Regulus Therapeutics Inc. (RGLS)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 11:54AM EDT. Market open.
| Previous close | 2.5100 |
| Open | 2.5300 |
| Bid | 2.6900 x 600 |
| Ask | 2.7300 x 400 |
| Day's range | 2.4900 - 2.7075 |
| 52-week range | 1.0800 - 3.7900 |
| Volume | |
| Avg. volume | 3,185,660 |
| Market cap | 176.429M |
| Beta (5Y monthly) | 1.55 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Regulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical Advancements
Financial and Clinical Progress Amidst Net Loss Wider Than Estimates
- Zacks
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Amylyx Pharmaceuticals (AMLX) and Acadia Pharmaceuticals (ACAD) plunged on failure of studies.
- Zacks
Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study
Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.
© 2024 Yahoo. All rights reserved.